# TERPS Trial for de Novo Oligometastic Prostate Cancer

> **NCT05223803** · PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 122 (estimated)

## Conditions studied

- Prostate Cancer
- Oligometastatic Disease

## Interventions

- **RADIATION:** Prostate radiation (XRT)
- **DRUG:** Systemic Therapy
- **RADIATION:** Stereotactic ablative radiation therapy (SABR)

## Key facts

- **NCT ID:** NCT05223803
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-18
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223803, "TERPS Trial for de Novo Oligometastic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05223803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*